<DOC>
	<DOCNO>NCT02178410</DOCNO>
	<brief_summary>The VITamin D OmegA-3 TriaL ( VITAL ) ongoing randomize clinical trial 25,874 U.S. men woman investigate whether take daily dietary supplement vitamin D3 ( 2000 IU ) omega-3 fatty acid ( OmacorÂ® fish oil , 1 gram ) reduce risk develop cancer , heart disease , stroke individual prior history illnesses.The purpose ancillary study ascertain adjudicate atrial fibrillation ( AF ) outcomes primary aim test whether omega-3 fatty acid and/or vitamin D supplementation influence atrial fibrillation risk general population . We also plan examine agent might impact intermediate phenotype heart rhythm disorder ( electrocardiographic parameter ) , well explore effect arrhythmic death whether baseline blood level and/or race modify treatment effect .</brief_summary>
	<brief_title>VITAL Rhythm Study</brief_title>
	<detailed_description>Atrial fibrillation sudden cardiac death assessment , well blood analysis , conduct entire VITAL Study population , ECG analyse limited Clinical Translational Science Center ( CTSC ) sub-cohort 1,054 VITAL participant live near Boston area agree participate series ancillary study addition main trial . Investigators ascertain atrial fibrillation event utilize self-report physician diagnose atrial fibrillation receive annual questionnaire study participant supplement outpatient hospital visit AF identify Centers Medicare Medicaid Services ( CMS ) data linkage . Investigators also ascertain additional information regard atrial fibrillation diagnosis supplementary questionnaire , seek consent review inpatient outpatient hospital record pertain atrial fibrillation diagnosis evaluation . Atrial fibrillation event confirm endpoint committee compose cardiologist , also make determination atrial fibrillation subtype pattern . An intention-to-treat analysis examine main effect omega-3 fatty acid vitamin D incident atrial fibrillation perform address primary aim . Electrocardiograms obtain baseline two year treatment follow-up among sub-cohort 1,054 patient enrol VITAL CTSC . Investigators utilize ECG data evaluate whether treatment omega-3 fatty acid vitamin D3 significant effect ECG measure . The ECGs also utilized estimate prevalence asymptomatic persistent atrial fibrillation population detect atrial fibrillation surveillance method . Investigators examine baseline blood sample estimate 500 participant confirm atrial fibrillation purpose explore whether effect vitamin D3 fish oil supplementation atrial fibrillation risk varies baseline blood level nutrient . Investigators also seek additional information necessary classify death sudden arrhythmic origin , cardiac death review endpoint committee cardiologist . Once result compile investigator explore whether omega-3 fatty acid and/or vitamin D might effect sudden and/or arrhythmic cardiac death .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>To eligible ancillary study participant must enrol Vitamin D Omega3 Trial ( VITAL ; National Clinical Trial ( NCT ) 01169259 ) meet follow criterion : physician diagnosis atrial fibrillation randomization and/or cardiovascular death physician diagnosis atrial fibrillation prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Vitamin D3</keyword>
	<keyword>Omega-3 fatty acid</keyword>
	<keyword>Fish oil</keyword>
</DOC>